Fig. 5

In vivo anti-tumor efficacy of 22B12 mAb. Mice were engrafted intra-mammary with BT20 cell line. After tumor growth, five mice per group received either 22B12 mAb or its corresponding isotype control (100 µg per injection twice weekly for two weeks). a Individual tumor growth in mice from the control (left) or 22B12 (right) group. b Same data as in (a) but expressed as the mean ± SD of each group over time. Arrows: mAb injections. Statistical comparison was performed with a Mann–Whitney t test. **p = 0.008 when compared to the control group